Corindus Equips the World’s First Fully Robotic Catheterization Laboratory
07 Maggio 2019 - 1:00PM
Business Wire
Chesapeake Regional Medical Center installs
CorPath® GRX Vascular Robotic Systems in all catheterization
labs
Corindus Vascular Robotics, Inc. (“Corindus” or
the “Company”) (NYSE American: CVRS), a leading developer of
precision vascular robotics, announced today that Chesapeake
Regional Healthcare in Chesapeake, VA has equipped both of its
catheterization labs at Chesapeake Regional Medical Center with
CorPath GRX Vascular Robotic Systems, making it the first hospital
in the world to adopt vascular robotic systems in all vascular
intervention treatment rooms. The outfitted labs will allow
physicians to leverage the latest robotic technology for
percutaneous coronary intervention (PCI) and peripheral vascular
intervention (PVI) and provide all patients requiring these
procedures at Chesapeake Regional access to the latest technology
in cardiovascular disease care.
“Through a full commitment to our technology, Chesapeake
Regional Medical Center has positioned itself as a premier vascular
treatment facility in the U.S.,” said Mark Toland, President and
Chief Executive Officer of Corindus. “Just a few months after their
first CorPath GRX purchase, strong physician demand led to the
purchase of a second system, offering all of their patients
suffering from heart disease the option of robotic treatment. In
addition, more physicians are opting to treat their patients at
Chesapeake Regional to provide them with the benefits of robotics
and the most advanced treatment options available. We want to
congratulate Chesapeake Regional on this landmark achievement and
for embracing robotic-assisted procedures to enhance patient care,”
added Toland.
The multi-system installation addresses the needs and demands of
the physicians, staff, and patients. The center is the first
non-academic hospital in the state of Virginia to launch a vascular
robotic program and perform a robotic-assisted PCI procedure using
the CorPath GRX System, and is the first facility in the world with
vascular robotic capabilities in all catheterization labs. Ronald
McKechnie, MD, Medical Director of the Catheterization Lab at
Chesapeake Regional Medical Center, performed the organization’s
first robotic-assisted PCI procedure on March 18, 2019.
“Since installing our first system, we have taken pride in
providing our patients with access to the most advanced treatment
options, while also providing our physicians and staff protection
from the daily occupational hazards involved with vascular
intervention,” said Dr. McKechnie. “Technological advances like
these will not only improve outcomes for our patients, but also
change the landscape for the future treatment of cardiovascular
disease everywhere. Patients are seeking robotic technology for
coronary care and we are thrilled to be a part of this
movement.”
To learn more about Corindus and CorPath GRX, please visit
www.corindus.com.
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics is a global technology leader in
robotic-assisted vascular interventions. The Company’s CorPath®
platform is the first FDA-cleared medical device to bring robotic
precision to percutaneous coronary and vascular procedures. CorPath
GRX is the second generation robotic-assisted technology offering
enhancements to the platform by adding important key upgrades that
increase precision, improve workflow, and extend the capabilities
and range of procedures that can be performed robotically. We are
focused on developing innovative robotic solutions to revolutionize
treatment of emergent conditions by providing specialized and
timely medical care to patients around the world. For additional
information, visit www.corindus.com, and follow @CorindusInc.
About Chesapeake Regional Healthcare
Chesapeake Regional Healthcare is home to Chesapeake Regional
Medical Center, the only independent, community-based hospital in
the Hampton Roads region providing technologically advanced health
care to the residents of southeastern Virginia and northeastern
North Carolina for more than 40 years. It offers a nationally
accredited Chest Pain Center, a Bariatric Surgery Center of
Excellence, several five-star ratings from Healthgrades® and one of
the busiest Emergency Departments and maternity wards in the area.
With more than 600 physicians on staff, the first da Vinci® XI
Surgical System in the state of Virginia and the first hospital in
the world to adopt CorPath GRX Vascular Robotic Systems in all
vascular intervention treatment rooms, Chesapeake Regional is
dedicated to putting patients first with the most advanced
treatments in health care and a personalized touch. For more
information, visit www.chesapeakeregional.com.
Forward Looking Statements
Statements made in this release that are not statements of
historical or current facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of Corindus to be materially
different from historical results or from any future results or
projections expressed or implied by such forward-looking
statements. Accordingly, readers should not place undue reliance on
any forward-looking statements. In addition to statements that
explicitly describe such risks and uncertainties, readers are urged
to consider statements in the conditional or future tenses or that
includes terms such as "believes," "belief," "expects,"
"estimates," "intends," "anticipates" or "plans" to be uncertain
and forward-looking. Forward-looking statements may include
comments as to Corindus’ beliefs and expectations as to future
events and trends affecting its business and are necessarily
subject to uncertainties, many of which are outside Corindus’
control.
Examples of such statements include statements regarding or such
as:
- More physicians are opting to treat
their patients at Chesapeake Regional to provide them with the
benefits of robotics and the most advanced treatment options
available.
- Technological advances like these will
not only improve outcomes for our patients, but also change the
landscape for the future treatment of cardiovascular disease
everywhere.
Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
are described in the sections titled "Risk Factors" in the
Company's filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as reports on Form 8-K, including,
but not limited to the following: our ability to expand our
technology platform and achieve the advances necessary for
telestenting and remote procedures, including in humans; our
ability to expand our technology platform for use in other segments
of the vascular intervention market, including neurointerventional
and other more complex cardiac interventions; obtaining necessary
regulatory approvals for the use on humans and marketing of our
products in the United States and in other countries, including for
stroke and other neurovascular interventions; the rate of adoption
of our CorPath System and the rate of use of our cassettes; risks
associated with market acceptance, including pricing and
reimbursement; our ability to enforce our intellectual property
rights; our need for additional funds to support our operations;
our ability to manage expenses and cash flow; factors relating to
engineering, regulatory, manufacturing, sales and customer service
challenges; potential safety and regulatory issues that could slow
or suspend our sales; and the effect of credit, financial and
economic conditions on capital spending by our potential customers.
Forward looking statements speak only as of the date they are made.
Corindus undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise that occur after that date. More
information is available on Corindus' website at
http://www.corindus.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190507005263/en/
Corindus:Media Contact:Matter for CorindusJessica
WolterT: 978-518-4536corindus@matternow.comwww.matternow.com
Investor Contact:Lisa WilsonIn-Site Communications, Inc.T:
917-543-9932ir@corindus.com
Chesapeake Regional Medical Center:Tricia HardyChesapeake
Regional HealthcareT:
757-312-6873Tricia.Hardy@chesapeakeregional.com
Grafico Azioni Corindus Vascular Robotics (AMEX:CVRS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Corindus Vascular Robotics (AMEX:CVRS)
Storico
Da Giu 2023 a Giu 2024